Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin inBRAFwild-type melanoma

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma

(2013) Xiaoqi Xie et al.   PLoS One

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

(2013) C. Posch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

(2012) L. C. W. Vredeveld et al.   GENES & DEVELOPMENT

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

(2012) I V Fedorenko et al.   ONCOGENE

Elucidating Distinct Roles for NF1 in Melanomagenesis

(2012) Ophélia Maertens et al.   Cancer Discovery

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

(2011) Inna V. Fedorenko et al.   BIOCHEMICAL PHARMACOLOGY

Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells

(2011) Guangmin Xi et al.   CANCER LETTERS

Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells

(2011) Ye Xu et al.   CANCER LETTERS

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma

(2011) X.-H. Ma et al.   CLINICAL CANCER RESEARCH

MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis

(2011) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy

(2010) Keiran S.M. Smalley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autophagy and Metabolism

(2010) J. D. Rabinowitz et al.   SCIENCE

Targeted deletion ofautophagy-related 5(atg5) impairs adipogenesis in a cellular model and in mice

(2009) Rebecca Baerga et al.   Autophagy

Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells

(2009) Damià Tormo et al.   CANCER CELL

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

(2009) SubbaRao V. Madhunapantula et al.   Pigment Cell & Melanoma Research

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

A novel AKT3 mutation in melanoma tumours and cell lines

(2008) M A Davies et al.   BRITISH JOURNAL OF CANCER

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

(2008) Victor Y. Yazbeck et al.   EXPERIMENTAL HEMATOLOGY

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

(2008) Michael Degtyarev et al.   JOURNAL OF CELL BIOLOGY

Mutant B-RAF mediates resistance to anoikis via Bad and Bim

(2008) K Boisvert-Adamo et al.   ONCOGENE

Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival

(2008) Robert A. Cartlidge et al.   Pigment Cell & Melanoma Research